Vaccines Research & Development

Register 3 for the price of 2 with the coupon code rcdvb!

Dear Colleague,

Recent headlines have been captivated by emerging infectious diseases from the recent Ebola outbreak in west Africa, to Zika in South America, to pandemic influenza around the globe. These emerging infections have been at the forefront of cutting-edge research, rapid product development and clinical evaluation and we are excited to invite you to join with colleagues from industry and academia to discuss them at GTCbio’s 15th Annual Vaccines Research & Development Conference. This meeting will take place July 13-14, 2017 in Baltimore, MD as part of the larger Infectious Diseases Summit.

Current support by NIH, DoD and BARDA, Eli Lilly, GlaxoSmithKline and more demonstrate recognition by federal agencies and large pharmaceutical companies the necessity for innovative vaccines for emerging pathogens. Therefore, the focus of this conference will be to evaluate the lessons learned from both the academic and industry responses during past epidemics for translation to next-generation research with new pathogens for use in future outbreaks. Sessions will focus on defining emerging global health threats (Zika, multi-drug resistant TB, influenza), discussing next generation technologies to address these foes (novel adjuvants, DC vaccines, nucleic acid vaccines, recombinant viral vectors) and addressing challenges to those goals.

Additionally, we will have a session focused on how best to create these assets for those most vulnerable – populations on both ends of the age spectrum – a topic that has recently arose as an important consideration. Over the course of this meeting attendees will have ample opportunity to engage and network with speakers and panelists.

Session Topics

  1. Plenary Session: Responding to Emerging Infectious Diseases on the Global Stage
  2. Vaccines for Infectious Diseases-Old & New Challenges
  3. Next-Generation Vaccine Technologies
  4. Enhancing Immunity at Both Ends of the Age Spectrum
  5. Panel: Clinical Trial Design during Epidemics
  6. General Session: Public/Private Partnerships in Support of Global Health

We hope to see you there!

Best regards,

The 2017 Advisory Committee

2017 Program Director
Alyson Smith, University of Montana, Inimmune Corp.
2017 Advisory Board Members
Ken Rosenthal, Roseman University of Health Sciences
Lynda Tussey, VaxInnate Corporation
Daniel Wolfe, Biomedical Advanced Research and Development Authority
Steven Bradfute, University of New Mexico
Shan Lu, University of Massachusetts Medical School
Suresh Mahalingam, Griffith University
Jeffrey Ulmer, GSK Vaccines
Steve Pascolo, University Hospital Zurich
Tong-Ming Fu, Merck
Annie De Groot, EpiVax
Dan Zimmerman, CEL-SCI Corporation
Richard Kornbluth, Multimeric Biotherapeutics, Inc.
Lenny Moise, EpiVax
Jay Evans, Inimmune Corp.

registration button

registration button

Subscribe for updates